Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedtideFRA:FQ2 -6.03%31 EV-to-FCF is 11.94 as of Sep. 02, 2026, which is 26% below its 10-year median of 16.21. GuruFocus rates FRA:FQ2 with a GF Score™ of 31/100. Among 316 Biotechnology companies, Medtide ranks better than 52.85% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Medtide's Enterprise Value is €198.49 Mil.
Medtide's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €16.62 Mil. Therefore, Medtide's EV-to-FCF for today is 11.94.
The historical rank and industry rank for Medtide's EV-to-FCF or its related term are showing as below:
FRA:FQ2'
s EV-to-FCF Range Over the Past 10 Years
Min: 9.74 Med: 16.21 Max: 50.05
Current: 12.64
During the past 5 years, the highest EV-to-FCF of Medtide was 50.05. The lowest was 9.74. And the median was 16.21.
FRA:FQ2's EV-to-FCF is ranked better than 52.85% of 316
companies
in the Biotechnology industry
Industry Median: 16.045
vs FRA:FQ2: 12.64
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medtide's share price for today is €2.18.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medtide's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.147.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Medtide EV-to-FCF Related Terms
Medtide EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Medtide's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Medtide's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medtide EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medtide's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Medtide's EV-to-FCF falls into.
Medtide's current Enterprise Value is €198.49 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medtide's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €16.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medtide (FRA:FQ2) has a EV-to-FCF of 11.94 as of Sep. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Medtide and its competitors. This is 26% below median its historical median of 16.21. Over the past decade, Medtide's EV-to-FCF has ranged from 9.74 to 50.05. According to the industry distribution chart, Medtide ranks #149 out of 316 companies in the Biotechnology industry, placing it in the top 47.2%.
Is Medtide's EV-to-FCF too high?
Medtide's current EV-to-FCF of 11.94 is 26% below median its 10-year median of 16.21. Over the past 10 years, this metric has ranged from a low of 9.74 to a high of 50.05. The Biotechnology industry median EV-to-FCF is 16.05. Medtide's value of 11.94 is 25.6% below this industry median. Based on the distribution chart, Medtide ranks #149 out of 316 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medtide has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Medtide's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medtide ranks #149 out of 316 companies for EV-to-FCF. This puts Medtide in the upper half of its industry. The industry median EV-to-FCF is 16.05. Medtide's value of 11.94 is 25.6% below this benchmark. Historically, Medtide's own EV-to-FCF has ranged from 9.74 to 50.05 over the past decade. While the company's 10-year median is 16.21 vs. the industry median of 16.05, Medtide has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.05, based on 316 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medtide's current EV-to-FCF of 11.94 is 25.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Medtide and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medtide's current EV-to-FCF is 11.94, which is 26% below median its own 10-year median of 16.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtide stock overvalued right now?
Medtide (FRA:FQ2) has a current EV-to-FCF of 11.94. The current EV-to-FCF is 11.94, which is 26% below median its 10-year median of 16.21 and 25.6% below the Biotechnology industry median of 16.05. Medtide's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Medtide (FRA:FQ2), the current EV-to-FCF is 11.94 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medtide Inc offers full-cycle services ranging from early-stage discovery, preclinical research and clinical development to commercial-stage production. It mainly provide (i) CRO services, namely peptide NCE discovery synthesis; and (ii) CDMO services, namely peptide CMC development and commercial manufacturing. Its services focus on providing customers with APIs rather than drug products. Geographically, the company generates majority of its revenue from USA.
31GF Score
Get the complete analysis for FRA:FQ2
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FQ2 has been successfully added to your 
